Sharps Technology Inc (STSS) Share Price

I would think a great demand on their products would result in big uptick in STSS price. Demand that wipes out the inventory is rather rare in my thinking! Thoughts? In at $ 1.80 ,$1.84, and $ 1.91

Sells out inventory. Hmmmmmmmm: Sharps Technology Signs Sales Agreements to Support Major European Healthcare Network and Sells Out Its Inventory for SecureGard
Signed multiple agreements to sell its SecureGard syringe inventory, with initial shipments and revenue commencing in early December
Agreements also include new forecasted orders and commitments for all current SecureGard capacity, to begin in Q2 2025
The SecureGard agreements will strengthen the potential revenue curve for the Hungary Operation starting in 2024
NEW YORK, Dec. 05, 2024 (GLOBE NEWSWIRE) -- Sharps Technology, Inc. (NASDAQ: “STSS” and “STSSW”), an innovative medical device and pharmaceutical packaging company offering patented, best-in-class syringe products, has begun deliveries of its 1mL and 3mL SecureGard safety syringes under the new sales agreements with a prominent European medical supply company serving Poland, Slovakia, and the Czech Republic. To meet demand in the region, Sharps’ customer has requested additional deliveries by year-end 2024 and committed to purchasing all available plant inventory by Q1 2025.

As a supplier to the largest network of hospitals and outpatient clinics in Central and Eastern Europe, the customer plans to purchase Sharps’ entire existing inventory of 1mL and 3mL SecureGard inventory warehoused in Hungary. This would be followed by new production orders starting in Q2 2025. These orders will consume all currently available SecureGard production capacity of 35 million units at the Hungary manufacturing facility. The customer has also expressed interest in Sharps’ U.S. inventory to fulfill a need for safety syringe supplies in Northern Africa.

The demand for Sharps’ innovative injection solutions continues to grow rapidly, with injectables remaining the preferred delivery method for therapies such as vaccines, biologics, weight loss and maintenance, ophthalmic and cosmetic applications, gene therapies, and diabetes and inflammatory disease management. With increasing levels of interest and potential demand for the Company’s high-quality smart safety syringe products in the region, Sharps is collaborating with both government and private investment sources in Hungary to expand the current manufacturing footprint and take advantage of the need to increase both SecureGard and SoloGard manufacturing capacity. The expansion will be planned to increase the annual SecureGard capacity to more than 100 million units, and the SoloGard capacity to more than 125 million units.

Sharps’ SecureGard and SoloGard product lines focus on low waste and ultra-low waste syringe technologies that also incorporate active safety features to fill the healthcare industry’s demand for the highest quality drug delivery solutions.

All inventory sold$$$$ 🚀🚀🚀🚀can we see $2.89- 3.85 profit zone 

Stick those needles up $2.73 + 40%! 2m floater

STSS new 52 week low

STSS anew 52=week low

Until when did the Nasdaq 180 day exemption give them? R/S could happen ...

STSS..........................................https://stockcharts.com/h-sc/ui?s=STSS&p=W&b=5&g=0&id=p86431144783

What's that?

Game! Blouses!

Just loud pipe down

my fist

no but i hate idiots with a big mouth

Shifting here Peter uterus

Who's to and who's bottom?

Must have struck a nerve

give me 1min and you cry for your mamma idiot

Tell your husband I said hi

$$$$$ in the pocket smarty

Large Red shoes red nose

Clowns working overtime solid news and company

The orders keep coming in...Bound to go up over time.

You're ready?

Nobody

down down down

Up up up

ouch...now you know who i am...watch and learn

They're trying hard

Faces could melt imo

STSS Sharps Technology Enters Into 5-Year Sales Agreement With Strategic U.S. Medical Products Company Creating +$50M In New Revenue For EU Facility, Definitive Agreement Sells Out The 10mL SoloGard Production Capacity At Sharps' Manufacturing Site
BENZINGA
53 mins ago
Definitive agreement sells out the 10mL SoloGard production capacity at Sharps' manufacturing site in the EU and drives expansion to support the project's growth in the future

Sharps' portfolio of products provides attractive options to the U.S. Pharmaceutical Healthcare Industry as companies look for alternatives to Chinese-manufactured disposable syringes

Sharps has exceeded the product sales commitments for the EU-based facility made to investors in the June 2022 Shareholder Letter

NEW YORK, July 25, 2024 (GLOBE NEWSWIRE) -- Sharps Technology, Inc. (STSS.NaE), , an innovative medical device and pharmaceutical packaging company offering patented, best-in-class prefillable and disposable syringe products, has successfully concluded negotiations and signed a contract with a prominent U.S.-based supplier of medical saline and water products to supply them with customized 10mL SoloGard syringes manufactured at Sharps' facility in the EU. The customer initiated an evaluation of Sharps' SoloGard product in light of the recent FDA recalls and tariffs imposed on Chinese supplied syringes. Their successful evaluation of the SoloGard syringes led to the execution of a five-year sales agreement that completely sells out the currently available manufacturing capacity for the 10mL SoloGard product. This transformative syringe program will drive the need for near-term expansion to support the current customer projects slated for the Hungary plant.

Bell about to ring get ready

Its up from here.

Theater get the popcorn

STSS In just under .34

Slide to the left then slide to the right

yup most of the time he right sold 385s

dumpty dumpty two by four...whos running through the bathroom door to puke their bags down the toilet lol

Following papi? Get ready!!

Sharps Technology Enters Into a Five-Year Sales Agreement with Strategic U.S. Medical Products Company Creating +$5O Million in New Revenue for EU Facility
Definitive agreement sells out the 10mL SoloGard production capacity at Sharps’ manufacturing site in the EU and drives expansion to support the project’s growth in the future

Sharps’ portfolio of products provides attractive options to the U.S. Pharmaceutical Healthcare Industry as companies look for alternatives to Chinese-manufactured disposable syringes

Sharps has exceeded the product sales commitments for the EU-based facility made to investors in the June 2022 Shareholder Letter

NEW YORK, July 25, 2024 (GLOBE NEWSWIRE) -- Sharps Technology, Inc., (NASDAQ: “STSS” and “STSSW”), an innovative medical device and pharmaceutical packaging company offering patented, best-in-class prefillable and disposable syringe products, has successfully concluded negotiations and signed a contract with a prominent U.S.-based supplier of medical saline and water products to supply them with customized 10mL SoloGard syringes manufactured at Sharps’ facility in the EU. The customer initiated an evaluation of Sharps’ SoloGard product in light of the recent FDA recalls and tariffs imposed on Chinese supplied syringes. Their successful evaluation of the SoloGard syringes led to the execution of a five-year sales agreement that completely sells out the currently available manufacturing capacity for the 10mL SoloGard product. This transformative syringe program will drive the need for near-term expansion to support the current customer projects slated for the Hungary plant.

“Creating a strategic partnership with the customer and selling out production capacity at the Hungary plant for the next five years is a historic accomplishment for Sharps and the future success of the Company,” stated Robert Hayes, CEO of Sharps Technology. “The collaboration creates a five-year sales agreement for at least 500 million syringes and essentially consumes the current available manufacturing capacity for Sharps’ 10mL SoloGard disposable syringe. This project also provides a clear path for near-term revenue for our company beginning in Q4 2024, with a phased ramp up into 2025.”

Filippo Filippi, General Manager of the SafeGard manufacturing facility, is pleased that his plant is delivering on commitments made by Sharps leadership in 2022. “We have been driven to bring our innovative syringes to the U.S. healthcare market,” says Filippi. “After two years of dedicated efforts, I am excited for this five-year commitment for the 500 million units, starting with the 10mL SoloGard shipments in November of this year. Equally as important, this sales agreement will help provide a solid foundation for the continued expansion of Sharps’ European division in Hungary.”

The Company believes that the need for innovative injection solutions continues to grow rapidly as injectables are the first choice for therapies as diverse as vaccines, biologics, weight loss and maintenance, ophthalmic and cosmetic applications, gene therapies, and diabetes and inflammatory disease management. As a result of this market growth and the impact of the tariffs, recalls, and quality issues with Chinese supplied syringes, Sharps is seeing increasing levels of interest and potential demand for its high-quality smart safety syringe products. Specializing in the development and manufacturing of innovative drug delivery systems, Sharps’ SecureGard and SoloGard product lines focus on low waste and ultra-low waste syringe technologies that also incorporate active safety features, as well as World Health Organization accredited re-use prevention measures.

About Sharps Technology
Sharps Technology is an innovative medical device and pharmaceutical packaging company offering patented, best-in-class smart-safety syringe products to the healthcare industry. The Company’s product lines focus on providing ultra-low waste capabilities, that incorporate syringe technologies that use both passive and active safety features. Sharps also offers products that are designed with specialized copolymer technology to support the prefillable syringe market segment. The Company has a manufacturing facility in Hungary and is partnering with Nephron Pharmaceuticals to expand its manufacturing capacity in the U.S. For more information about Sharps Technology, please visit the website at: http://sharpstechnology.com.

FORWARD-LOOKING STATEMENTS:
This press release contains “forward-looking statements”. Forward-looking statements reflect our current view about future events. When used in this press release, the words “anticipate,” “believe,” “estimate,” “expect,” “future,” “intend,” “plan,” “poised” or the negative of these terms and similar expressions, as they relate to us or our management, identify forward-looking statements. Such statements, include, but are not limited to, statements contained in this press release relating to our business strategy, our future operating results and liquidity, and capital resources outlook. Forward-looking statements are based on our current expectations and assumptions regarding our business, the economy, and other future conditions. Because forward–looking statements relate to the future, they are subject to inherent uncertainties, risks, and changes in circumstances that are difficult t

i know im out

teach the clowns a lesson...its a full time job

you re right, its toast and am out. I only like the 1min staircases and scalped some lunch money.
Happy trading

dilute into noise...volume can be deceptive...warrants warrants galore...may 24th 1-a 47 million shares...yikes

dont get burned old man

my screen shows +15% since we started talking like 2 minutes ago
now enough of this tomfoolery.

chase above a top w band can lead to ulcers

Hold on to your undies

Lol

top weekly band .37c...weekly chart ugly

arent you the guy calling yourself "master" and others "son"?
as we speak the stock made a new high